Cancer Research Cell Death Mechanisms and Cancer Therapy  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stefansson, I. M.
Right arrow Articles by Akslen, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefansson, I. M.
Right arrow Articles by Akslen, L. A.
[Cancer Research 66, 3303-3309, March 15, 2006]
© 2006 American Association for Cancer Research


Clinical Research

Vascular Proliferation Is Important for Clinical Progress of Endometrial Cancer

Ingunn M. Stefansson1, Helga B. Salvesen1,2 and Lars A. Akslen1

1 The Gade Institute, Section for Pathology and 2 Department of Clinical Medicine, Section for Gynecology and Obstetrics, University of Bergen, Haukeland University Hospital, Bergen, Norway

Requests for reprints: Lars A. Akslen, Children's Hospital, Harvard Medical School, Vascular Biology Program (Folkman Lab), Karp Family Research Labs 12.125, 300 Longwood Avenue, Boston, MA 02115-5737. Phone: 617-919-2426; Fax: 617-739-5891; E-mail: lars.akslen{at}childrens.harvard.edu or lars.akslen{at}gades.uib.no.

Angiogenesis is essential for tumor growth, invasion, and metastatic spread. Whereas microvessel density (MVD) has been widely used as a measure of tumor-associated angiogenesis, we now wanted to examine the significance of other angiogenic markers, especially vascular proliferation (by Ki-67/factor VIII staining) and the degree of pericyte coverage [by {alpha}-smooth muscle actin ({alpha}-SMA)/factor VIII staining], in a large and population-based series of endometrial carcinoma with complete follow-up. Due to limited information on the role of lymphangiogenesis in these tumors, lymphatic vessel density (LVD) by LYVE-1 staining was also determined, as well as selected angiogenic factors [vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-D and basic fibroblast growth factor (bFGF)], which could possibly be related to vascular proliferation and lymphangiogenesis. The information on angiogenic phenotype was related to clinicopathologic features and disease progress. Median vascular proliferation, as estimated by vascular proliferation index (VPI), was 3.9% and high VPI was associated with features of aggressive tumors and decreased survival. The prognostic effect of VPI was superior to that of MVD. Presence of pericyte coverage, as estimated by the {alpha}-SMA index (SMAI), was 35% and low SMAI was significantly associated with vascular invasion by tumor cells and impaired prognosis. Peritumoral lymphatic vessels (LVD-pt) were found in 39.5% of the cases and high LVD-pt was significantly associated with aggressive tumor features and decreased survival. In multivariate survival analysis, only the extent of vascular proliferation had independent prognostic effect, in addition to well-known clinicopathologic factors, whereas MVD did not have significant prognostic value. In conclusion, our study indicates that vascular proliferation is a meaningful variable in assessing the angiogenic phenotype of endometrial carcinoma. (Cancer Res 2006; 66(6): 3303-9)




This article has been cited by other articles:


Home page
Cancer Res.Home page
K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen
Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer
Cancer Res., June 1, 2009; 69(11): 4708 - 4715.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. N. Naumov, M. B. Nilsson, T. Cascone, A. Briggs, O. Straume, L. A. Akslen, E. Lifshits, L. A. Byers, L. Xu, H.-k. Wu, et al.
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
Clin. Cancer Res., May 15, 2009; 15(10): 3484 - 3494.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. A. Kamat, W. M. Merritt, D. Coffey, Y. G. Lin, P. R. Patel, R. Broaddus, E. Nugent, L. Y. Han, C. N. Landen Jr., W. A. Spannuth, et al.
Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer
Clin. Cancer Res., December 15, 2007; 13(24): 7487 - 7495.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. F. Donoghue, F. L. Lederman, B. J. Susil, and P. A.W. Rogers
Lymphangiogensis of normal endometrium and endometrial adenocarcinoma
Hum. Reprod., June 1, 2007; 22(6): 1705 - 1713.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Takahashi, Y. Akishima-Fukasawa, N. Kobayashi, T. Sano, T. Kosuge, Y. Nimura, Y. Kanai, and N. Hiraoka
Prognostic Value of Tumor Architecture, Tumor-Associated Vascular Characteristics, and Expression of Angiogenic Molecules in Pancreatic Endocrine Tumors
Clin. Cancer Res., January 1, 2007; 13(1): 187 - 196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.